H.C. Wainwright downgraded Marinus Pharmaceuticals (MRNS) to Neutral from Buy with a price target of $2, down from $11. The firm is “disappointed” after Marinus reported that ganaxolone failed in its pivotal trial to treat refractory TSC-associated seizures. This is the second significant setback for Marinus this year following the miss in refractory status epilepticus earlier in the spring, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals downgraded to Hold from Buy at TD Cowen
- Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies
- Marinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton
- Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird
- Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities